Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer gr... - 0 views
-
Matti Narkia on 14 Apr 09PHILADELPHIA - Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.